Monte Rosa Therapeutics Inc
GLUE
查看详细走势图
19.550USD
+0.650+3.44%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.21B总市值
61.50市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.44%
5天
-4.73%
1月
-16.02%
6月
+362.17%
今年开始到现在
+24.68%
1年
+190.06%
查看详细走势图
TradingKey Monte Rosa Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Monte Rosa Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名45/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价29.29。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Monte Rosa Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Monte Rosa Therapeutics Inc亮点
亮点风险
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
业绩增长期
公司处于发展阶段，最新年度总收入75.62M美元
估值高估
公司最新PE估值61.50，处于3年历史高位
机构加仓
最新机构持股70.21M股，环比增加1.50%
查克·罗伊斯持仓
明星投资者查克·罗伊斯持仓，最新持仓市值11.02K
分析师目标
根据
9
位分析师
买入
评级
29.286
目标均价
+49.95%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Monte Rosa Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Monte Rosa Therapeutics Inc简介
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
公司代码GLUE
公司Monte Rosa Therapeutics Inc
CEOWarmuth (Markus)
网址https://www.monterosatx.com/
相关品种
